Compugen News

News

Ticker

CGEN

ISIN

IL0010852080

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Compugen Eulerpool News

Compugen Stock News

Compugen is being monitored by journalists and investors worldwide. We gather the latest Compugen news here.

March 2·
SeekingAlpha
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement
March 2·
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 2·
SeekingAlpha
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
March 2·
Benzinga
Compugen Says It Is On Track To Have MAIA-Ovarian Interim Analysis In Q1 2027
March 2·
Benzinga
Earnings Breakdown: Compugen Q4
March 2·
Benzinga
Compugen Q4 EPS $0.60 Beats $0.05 Estimate, Sales $67.332M Beat $1.357M Estimate
March 2·
Benzinga
Earnings Scheduled For March 2, 2026
February 27·
Benzinga
Uncovering Potential: Compugen's Earnings Preview
February 26·
Yahoo
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
February 26·
Yahoo
Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates
February 19·
Yahoo
Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
February 19·
Yahoo
Compugen to Participate in Upcoming Investor Conferences
February 17·
Yahoo
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
February 12·
Yahoo
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
December 17·
Benzinga
Compugen Agrees With AstraZeneca To Monetize Portion Of Compugen's Rilvegostomig Future Royalties
November 10·
Yahoo
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates
November 10·
Yahoo
Compugen Reports Third Quarter 2025 Results
November 10·
SeekingAlpha
Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript
August 9·
Yahoo
Need To Know: Analysts Just Made A Substantial Cut To Their Compugen Ltd. (NASDAQ:CGEN) Estimates
August 8·
SeekingAlpha
Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients

Compugen Stock Press Releases

Compugen regularly publishes news on the company's website that are relevant for investors.

August 8•
Compugen
Compugen Expands anti-PVRIG COM701 Intellectual Property Portfolio
August 4•
Compugen
Compugen Reports Second Quarter 2022 Results
July 21•
Compugen
Compugen to Release Second Quarter Results on Thursday, August 4, 2022
June 27•
Compugen
Compugen to Present at Upcoming Industry Conferences
June 1•
Compugen
Compugen to Present at Upcoming Investor Conferences
May 16•
Compugen
Compugen Reports First Quarter 2022 Results
May 10•
Compugen
Compugen Announces CFO Departure
May 2•
Compugen
Compugen to Release First Quarter 2022 on Monday, May 16, 2022
March 21•
Compugen
Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of the Tumor Microenvironment
March 14•
Compugen
Compugen To Present New Insights into the Tumor Microenvironment Using Single Cell Spatial Transcriptomics at Keystone Symposium
March 9•
Compugen
Compugen to Present at the Oppenheimer 32nd Annual Global Healthcare Conference
March 9•
Compugen
Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple Myeloma
February 24•
Compugen
Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
February 24•
Compugen
Compugen Reports Fourth Quarter and Full Year 2021 Results
February 10•
Compugen
Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022
February 9•
Compugen
Compugen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
January 18•
Compugen
Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies
December 9•
Compugen
Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit
November 12•
Compugen
Compugen Reports Third Quarter 2021 Results
November 8•
Compugen
Compugen to Present at Upcoming Investor Conferences
October 26•
Compugen
Compugen to Release Third Quarter 2021 Results on Friday, November 12, 2021
October 1•
Compugen
Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021
September 14•
Compugen
Compugen to Present at the Cantor Global Healthcare Conference
August 26•
Compugen
Compugen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
August 19•
Compugen
Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development
July 28•
Compugen
Compugen Reports Second Quarter 2021 Results
July 19•
Compugen
Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207
July 15•
Compugen
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies
July 14•
Compugen
Compugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021
June 30•
Compugen
Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study

Compugen News 2026

This page contains all current news, analysis and press releases for Compugen stock (CGEN, ISIN: IL0010852080). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Compugen.

Compugen Stock

Compugen Compugen Ltd is an Israeli biotechnology company focused on the development of therapeutics and diagnostic products. It was founded in 1993 and is headquartered in Tel Aviv.